Research Paper Volume 12, Issue 18 pp 18297—18321

Glioblastoma cell differentiation trajectory predicts the immunotherapy response and overall survival of patients

Figure 8. Prognostic nomogram to predict the 0.5-, 1-, and 3-year OS of GBM patients. (A) Nomogram model to predict the prognosis of GBM patients based on the TCGA training cohort. Age, pharmacotherapy, radiotherapy, IDH mutation status, MGMT promoter methylation status, and the GDRG signature were included in the prediction model. The prognostic performance of the nomogram demonstrated by the time-dependent ROC curve for predicting the 0.5-, 1-, and 3-year OS rates in the TCGA training cohort (B) and CGGA validation cohort (C). Calibration plots of the prognostic nomogram for predicting OS at 0.5, 1, and 3 years in the TCGA (DF) and CGGA (GI) cohorts. Actual survival is plotted on the y-axis, and nomogram-predicted probability is plotted on the x-axis.